Riding the Waves of Obesity Science – Amylin at a Glance: A Mechanistic Map of a Systems Satiety Signal

Obesity care is moving quickly past the one-drug, one-pathway era. Current therapies have reshaped what treatment can achieve, yet responses vary widely and not every patient tolerates or responds to them, leaving clinicians searching for the next complementary mechanism. Amylin is among the most compelling. A hormone most clinicians last encountered as insulin’s co‑secreted partner, amylin is now understood as a systems‑level satiety signal with distinctive receptor biology and promise as monotherapy or in combination strategies. For many obesity‑medicine clinicians, though, that knowledge still stops at “co‑secreted with insulin,” a gap that makes it hard to interpret the growing body of investigational amylin data, distinguish selective amylin analogs from dual amylin and calcitonin receptor agonists (DACRAs), or judge where these agents fit within chronic, multi‑pathway disease management.

In this second CMEO Snack of the Riding the Waves of Obesity Science series, amylin researcher Matthew R. Hayes, PhD joins moderator Robert F. Kushner, MD for a focused, practical conversation that turns amylin from a half‑remembered footnote into working clinical knowledge; what amylin actually does, how its calcitonin‑receptor/receptor activity-modifying protein (RAMP) biology shapes today’s drug classes, and why its signal complements rather than duplicates glucagon-like peptide-1 (GLP‑1). Designed for physicians, nurse practitioners, physician associates, and pharmacists across obesity medicine, endocrinology, primary care, and cardiometabolic practice, this activity will help you read the emerging science with a sharper eye and be ready for the amylin‑based therapies that may be on the horizon.

At the conclusion of this activity, learners will be able to better:

• Evaluate the physiologic role of amylin in energy and glucose regulation
• Assess how amylin receptor biology supports complementary therapeutic strategies

Supported by an educational grant from Novo Nordisk Inc.

Obesity medicine clinicians [physicians, nurse practitioners (NPs), physician associates (PAs), pharmacists] involved in weight management and metabolic care, including endocrinology, primary care, cardiology/metabolic clinics, and obesity medicine settings

It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and mitigated any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Dr. Kushner reports the following financial relationships:

Advisory Board: Abbvie Inc; Antag Therapeutics; AstraZeneca; Boehringer Ingelheim; Currax Pharmaceuticals; Eli Lilly; Novo Nordisk; Structure Therapeutics, Inc.; Viking Therapeutics; and Weight Watchers

Dr. Hayes reports the following financial relationships:

Advisory Board: Abalone Bio

Consultant: Eli Lilly

Research Support: The Hayes lab at the University of Pennsylvania receives research funding from Boehringer Ingelheim; Coronation Bio, Inc; Eli Lilly; Kailera Therapeutics; and Protagonist Therapeutics Inc

Other financial or material support: MRH is a founding scientist of Coronation Bio, Inc; and Melogy Therapeutics that pursues biological work for the treatment of obesity.

The following individuals have no financial relationships to disclose:

Jeffrey Helfand, DO (Peer Reviewer)
Shirley Michelle Franks, DNP, APRN, FNP-BC, PMC MSN Ed (Peer Reviewer)
Mary Gleason, PhD, CHCP (Planning Committee)
Warren Beckman (Planning Committee)
Andrea Perseghin, EdD (Planning Committee)
Sandra Caballero, PharmD (Planning Committee)
Sharon Tordoff (Planning Committee)

*All identified conflicts of interest have been mitigated.

Unlabeled Use Disclosure
Faculty of this CME/CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices. CME Outfitters, LLC, the faculty, planners, and reviewers do not endorse the use of any product outside of the FDA labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.

Post-tests, credit request forms, and activity evaluations must be completed online (requires free account activation), and participants can print their certificate or statement of credit immediately (70% pass rate required). This website supports all browsers except Internet Explorer for Mac.

Call us at 877.CME.PROS (877.263.7767).

SN-315-082126-68